Summary & Overview
HCPCS J0605: Sucroferric Oxyhydroxide 5 mg for ESRD on Dialysis
HCPCS Level II code J0605 identifies sucroferric oxyhydroxide, oral, 5 mg, a phosphate binder indicated for patients with end-stage renal disease on dialysis. This code is relevant nationally for dialysis providers, outpatient pharmacies, and payers managing medication coverage for chronic kidney disease complications. Proper coding ensures appropriate billing for a specialty oral medication used in the dialysis population and supports tracking of therapy utilization and costs.
Key payers discussed in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise clinical context for the medication, typical sites of service, and an overview of payer coverage patterns. The publication also summarizes benchmark considerations, relevant billing practices, and potential policy updates that affect reimbursement and formulary placement. Practical elements covered include claims coding nuances for HCPCS Level II code J0605, implications for pharmacy and dialysis clinic workflows, and factors payers consider when authorizing this therapy.
Data not available in the input for specific associated taxonomies, ICD-10 diagnoses, related codes, and detailed payer policy language. The content is intended for a national audience of clinicians, billing staff, and policy analysts seeking a clear reference on the clinical and billing identity of HCPCS Level II code J0605.
Billing Code Overview
HCPCS Level II code J0605 represents sucroferric oxyhydroxide, oral, 5 mg formulated for patients with end-stage renal disease (ESRD) on dialysis. This code denotes a prescription oral phosphate binder used to manage hyperphosphatemia in dialysis-dependent patients.
Service type: Oral prescription medication for ESRD on dialysis
Typical site of service: Outpatient pharmacy or dialysis clinic medication administration
Clinical & Coding Specifications
Clinical Context
A 62-year-old patient with end-stage renal disease (ESRD) on maintenance hemodialysis is prescribed J0605 (sucroferric oxyhydroxide) 5 mg oral tablets as a phosphate binder to manage persistent hyperphosphatemia despite dietary phosphate restriction. The clinical workflow begins during a nephrology outpatient dialysis clinic visit or during a dialysis treatment session when serum phosphorus is evaluated. If serum phosphorus remains above target (commonly >5.5 mg/dL), the nephrologist reviews medication options and documents the indication for an oral iron-based phosphate binder. A prescription is written and the medication is administered or dispensed per facility policy; patient education is provided regarding timing relative to meals and other oral medications (for example, separate dosing from levothyroxine or certain antibiotics). Pharmacy dispensing is coded using HCPCS Level II code J0605 for billing to payors. Follow-up includes monitoring serum phosphorus, iron indices, and adherence at subsequent dialysis sessions and nephrology visits. Typical sites of service include outpatient dialysis centers and outpatient pharmacies associated with dialysis clinics. Documentation required for billing includes the ESRD diagnosis, clinical rationale for phosphate binder therapy, dosage and quantity, administration or dispensation record, and any relevant prior authorization or payer-specific documentation requirements.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|